C17orf75

Across TCGA pan-cancer cohorts, C17orf75 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C17orf75 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C17orf75 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C17orf75 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where C17orf75 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.643	0.912	.001	47	view →
LUAD	DFS	Quartile	All	0.525	0.817	.018	7	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.572	.035	4	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.798	.031	3	view →
CCRCC	DFS	Median	II,III,IV	0.938	0.799	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

C17orf75–PDAC (DFS)

Open the PDAC breakdown →